西妥昔单抗治疗结直肠癌的获益预测因素：我们是否“迷失在翻译中”？ - Suppr

Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?

作者信息

Cremolini Chiara, Loupakis Fotios, Ruzzo Annamaria, Perrone Giuseppe, Rulli Eliana, Vincenzi Bruno, Tonini Giuseppe, Graziano Francesco, Muda Andrea Onetti, Falcone Alfredo

出版信息

J Clin Oncol. 2010 Apr 10;28(11):e173-4; author reply e175-6. doi: 10.1200/JCO.2009.26.6148. Epub 2010 Feb 22.

DOI:10.1200/JCO.2009.26.6148

PMID:20177018

Abstract

摘要

相似文献

Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?西妥昔单抗治疗结直肠癌的获益预测因素：我们是否“迷失在翻译中”？

J Clin Oncol. 2010 Apr 10;28(11):e173-4; author reply e175-6. doi: 10.1200/JCO.2009.26.6148. Epub 2010 Feb 22.

KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.结直肠癌肿瘤中的KRAS突变特征与西妥昔单抗反应特征显著重叠。

J Clin Oncol. 2008 May 1;26(13):2228-30; author reply 2230-1. doi: 10.1200/JCO.2007.15.9186.

[Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].[表皮生长因子受体信号通路突变与转移性结直肠癌的治疗]

Gan To Kagaku Ryoho. 2010 May;37(5):791-4.

[Biology applied to cancer treatments: the example of colorectal cancer].[应用于癌症治疗的生物学：以结直肠癌为例]

Rev Prat. 2010 Oct 20;60(8):1100-2.

Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?在接受西妥昔单抗治疗的晚期结直肠癌患者中，KRAS突变应被视为一个独立的预后因素吗？

J Clin Oncol. 2008 May 20;26(15):2600; author reply 2601-2. doi: 10.1200/JCO.2008.16.8195.

To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.对于晚期结直肠癌中存在KRAS G13D突变的患者，是否给予抗表皮生长因子受体（EGFR）单克隆抗体治疗。

Clin Colorectal Cancer. 2012 Jun;11(2):85-7. doi: 10.1016/j.clcc.2011.10.005. Epub 2011 Dec 9.

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.分析PTEN、BRAF和EGFR状态以确定野生型KRAS转移性结肠癌患者从西妥昔单抗治疗中获益的情况。

J Clin Oncol. 2009 Dec 10;27(35):5924-30. doi: 10.1200/JCO.2008.21.6796. Epub 2009 Nov 2.

Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.结直肠癌：西妥昔单抗、KRAS、BRAF、PIK3CA突变及其他相关研究

Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):525-9. doi: 10.1586/egh.10.62.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.野生型BRAF是转移性结直肠癌对帕尼单抗或西妥昔单抗产生反应所必需的。

J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.

Chemotherapy and immunotherapy in metastatic colorectal cancer.转移性结直肠癌的化疗与免疫治疗

N Engl J Med. 2009 May 14;360(20):2135; author reply 2135-6.

引用本文的文献

Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials.贝伐珠单抗联合化疗作为右半转移性结直肠癌一线治疗的最佳选择：一线临床试验的荟萃分析。

ESMO Open. 2020 Mar;4(Suppl 2). doi: 10.1136/esmoopen-2019-000605.

EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.表皮生长因子受体配体作为西妥昔单抗和伊立替康治疗转移性结直肠癌患者的药效学生物标志物。

Target Oncol. 2014 Sep;9(3):205-14. doi: 10.1007/s11523-013-0284-7. Epub 2013 Jul 3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献